JP2017519768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519768A5 JP2017519768A5 JP2016573926A JP2016573926A JP2017519768A5 JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5 JP 2016573926 A JP2016573926 A JP 2016573926A JP 2016573926 A JP2016573926 A JP 2016573926A JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding fragment
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 239000012634 fragment Substances 0.000 claims description 63
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 241000894006 Bacteria Species 0.000 claims description 16
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 11
- 101710197219 Alpha-toxin Proteins 0.000 claims description 11
- 101710124951 Phospholipase C Proteins 0.000 claims description 11
- 239000002776 alpha toxin Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 241000589291 Acinetobacter Species 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 230000001332 colony forming effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 67
- 241000588748 Klebsiella Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 206010051548 Burn infection Diseases 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010036410 Postoperative wound infection Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014506P | 2014-06-19 | 2014-06-19 | |
| US62/014,506 | 2014-06-19 | ||
| US201562140849P | 2015-03-31 | 2015-03-31 | |
| US62/140,849 | 2015-03-31 | ||
| PCT/US2015/036576 WO2015196011A1 (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209896A Division JP2021063090A (ja) | 2014-06-19 | 2020-12-18 | 多細菌性感染の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519768A JP2017519768A (ja) | 2017-07-20 |
| JP2017519768A5 true JP2017519768A5 (enExample) | 2018-08-09 |
| JP6845016B2 JP6845016B2 (ja) | 2021-03-17 |
Family
ID=54936121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573926A Active JP6845016B2 (ja) | 2014-06-19 | 2015-06-19 | 多細菌性感染の治療 |
| JP2020209896A Pending JP2021063090A (ja) | 2014-06-19 | 2020-12-18 | 多細菌性感染の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209896A Pending JP2021063090A (ja) | 2014-06-19 | 2020-12-18 | 多細菌性感染の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168132B2 (enExample) |
| EP (1) | EP3157565B1 (enExample) |
| JP (2) | JP6845016B2 (enExample) |
| KR (1) | KR102549870B1 (enExample) |
| CN (1) | CN106456767B (enExample) |
| AU (1) | AU2015276938B2 (enExample) |
| CA (1) | CA2952278A1 (enExample) |
| ES (1) | ES2983252T3 (enExample) |
| SG (2) | SG10201811361XA (enExample) |
| TW (1) | TWI719938B (enExample) |
| WO (1) | WO2015196011A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2718320T3 (en) | 2011-06-10 | 2018-03-26 | Medimmune Ltd | ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF |
| US10597439B2 (en) | 2011-11-07 | 2020-03-24 | Medimmune Limited | Combination therapies using anti-pseudomonas PSL and PCRV binding molecules |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| CN104780934A (zh) | 2012-11-06 | 2015-07-15 | 米迪缪尼有限公司 | 治疗金黄色葡萄球菌相关疾病的方法 |
| SG10201913100WA (en) | 2015-11-30 | 2020-03-30 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
| AU2017261374B2 (en) | 2016-05-05 | 2024-06-20 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs for use against pseudomonas aeruginosa |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| BR112021006704A2 (pt) | 2018-10-09 | 2021-08-10 | Medimmune, Llc | anticorpos dirigidos contra leucotoxinas de staphylococcus aureus |
| GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| WO2020185986A1 (en) * | 2019-03-13 | 2020-09-17 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
| US11655286B2 (en) * | 2019-06-11 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| FR3114970B1 (fr) | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2025117765A1 (en) * | 2023-12-01 | 2025-06-05 | University Of Washington | Protective monoclonal antibodies to pseudomonas aeruginosa |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090019007A (ko) | 2006-06-12 | 2009-02-24 | 나비 바이오파마슈티컬즈 | 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도 |
| CA2784033A1 (en) * | 2009-12-22 | 2011-07-21 | Kalobios Pharmaceuticals, Inc. | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
| EP2673373B3 (en) * | 2011-02-08 | 2021-06-02 | MedImmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| US10597439B2 (en) * | 2011-11-07 | 2020-03-24 | Medimmune Limited | Combination therapies using anti-pseudomonas PSL and PCRV binding molecules |
| AU2013341349A1 (en) * | 2012-11-06 | 2015-05-21 | Medimmune Limited | Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules |
| SG11201503232TA (en) | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| CN104780934A (zh) | 2012-11-06 | 2015-07-15 | 米迪缪尼有限公司 | 治疗金黄色葡萄球菌相关疾病的方法 |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2015
- 2015-06-18 TW TW104119861A patent/TWI719938B/zh active
- 2015-06-19 US US15/319,958 patent/US11168132B2/en active Active
- 2015-06-19 CN CN201580032548.7A patent/CN106456767B/zh active Active
- 2015-06-19 CA CA2952278A patent/CA2952278A1/en active Pending
- 2015-06-19 WO PCT/US2015/036576 patent/WO2015196011A1/en not_active Ceased
- 2015-06-19 KR KR1020167034742A patent/KR102549870B1/ko active Active
- 2015-06-19 EP EP15809174.4A patent/EP3157565B1/en active Active
- 2015-06-19 SG SG10201811361XA patent/SG10201811361XA/en unknown
- 2015-06-19 AU AU2015276938A patent/AU2015276938B2/en active Active
- 2015-06-19 JP JP2016573926A patent/JP6845016B2/ja active Active
- 2015-06-19 SG SG11201609652RA patent/SG11201609652RA/en unknown
- 2015-06-19 ES ES15809174T patent/ES2983252T3/es active Active
-
2020
- 2020-12-18 JP JP2020209896A patent/JP2021063090A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519768A5 (enExample) | ||
| JP2021063090A5 (enExample) | ||
| King | Bronchiectasis | |
| JP6845016B2 (ja) | 多細菌性感染の治療 | |
| DiGiandomenico et al. | Antibacterial monoclonal antibodies: the next generation? | |
| US11911472B2 (en) | Monoclonal antibody and vaccine targeting filamentous bacteriophage | |
| Sulakvelidze et al. | Bacteriophages as therapeutic agents | |
| Munita et al. | Enterococcal endocarditis: can we win the war? | |
| JP2016507470A5 (enExample) | ||
| JP2013515079A5 (enExample) | ||
| RU2016116949A (ru) | Анти-лпс о11-антитело | |
| JP2018529661A5 (enExample) | ||
| JP2015536951A5 (enExample) | ||
| WO2020201833A8 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| JP2012516897A5 (enExample) | ||
| US20060153857A1 (en) | Method of treating staphylococcus aureus infection | |
| Binar et al. | An unusual cause of necrosis and nasal septum perforation after septoplasty: Enterobacter cloacae | |
| Tur | Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018 | |
| Koff et al. | Clinical use of inhaled bacteriophages to treat multi-drug resistant Pseudomonas aeruginosa | |
| Kim et al. | Infective endocarditis prophylaxis before dental procedures: New guidelines spark controversy | |
| Projan | Antibodies for the Prevention, Treatment, and Preemption of Infectious Diseases | |
| Tümmler | aeruginosa [version 1; peer review: 2 approved] | |
| AI Valasidis et al. | Novel antimicrobial agents for the management of maxillofacial and neck infections | |
| Burkhard | Emerging therapies against infections with Pseudomonas aeruginosa | |
| Popescu et al. | ROLE OF NEW FLUOROQUINOLONES IN THE TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS |